Back to Agenda
Session 5: Specialist approaches to complex therapies and product transitions
Session Chair(s)
Sarah Dunnett
Medical Operations Partner, Sarah Dunnett Consulting Ltd, United Kingdom
While the principles of Medical Information prevail, we recognise that some products require a tailored approach relative to the rest of the company’s portfolio or at different stages in their life cycle. We will learn why and how Pfizer have established their dedicated oncology service, how Gilead have chosen to support their novel CAR-T therapy (a patient specific cell therapy) and how GSK and Aspen Pharma have collaborated to achieve a smooth and professional handover of medical information responsibilities as products transitioned.
Speaker(s)
Specialized dedicated MI Oncology Frontline
Senior Medical Information Specialist, Pfizer, Portugal
Setting up a MI Service for CAR-T
, Gilead, United Kingdom
Product Divestments and Acquisitions: The Value and Impact on Medical Information
Director, Medical Information, GlaxoSmithKline, United Kingdom
Vinod Koshy, MPHARM, RPH
Head of Medical Information and Promotional Compliance, Aspen Pharmacare, Ireland
Have an account?